Brought to you by 
Roche acquires key gene therapy player Spark Therapeutics for $4.8bn
17 Dec 2019
Executive Summary
Roche acquired publicly traded gene therapy company Spark Therapeutics Inc. for $4.8bn, or $114.50 per share (a 128% premium), including $500mm of projected net cash at closing. Spark will continue to operate as an independent entity.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche acquires key gene therapy player Spark Therapeutics for $4.8bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice